Figure_2.tif (1.2 MB)
Download file

HLA class II-restricted IDOlong responses as measured by IFN-γELISPOT.

Download (0 kB)
posted on 20.02.2013, 06:05 by Shamaila Munir, Stine Kiaer Larsen, Trine Zeeberg Iversen, Marco Donia, Tobias Wirenfeldt Klausen, Inge Marie Svane, Per thor Straten, Mads Hald Andersen

PBMC from one renal cell carcinoma patient (A) and five melanoma patients (B,C,D,E,F) were stimulated once with peptide before being plated at either 2×105 or 5×105 cells per well in duplicates either without or with the IDOlong peptide or without and with a monoclonal anti-HLA class II antibody. The average number of IFN-γ releasing cells was calculated either per 2×105 PBMC or 5×105 PBMC for each patient.


Usage metrics